Division of Systems Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
J Neurochem. 2023 Nov;167(4):520-537. doi: 10.1111/jnc.15980. Epub 2023 Oct 11.
Amyloid-β (Aβ) and hyper-phosphorylated tau are key hallmarks of Alzheimer's disease (AD), with an accumulation of both proteins linked to hippocampal synaptic dysfunction. Recent evidence indicates that Aβ drives mis-localisation of tau from axons to synapses, resulting in AMPA receptor (AMPAR) internalisation and impaired excitatory synaptic function. These tau-driven synaptic impairments are thought to underlie the cognitive deficits in AD. Consequently, limiting the synapto-toxic effects of tau may prevent AD-related cognitive deficits. Increasing evidence links leptin dysfunction with higher AD risk, and numerous studies have identified neuroprotective properties of leptin in AD models of Aβ-induced toxicity. However, it is unclear if leptin protects against tau-related synaptic dysfunction. Here we show that Aβ significantly increases dendritic and synaptic levels of tau and p-tau in hippocampal neurons, and these effects were blocked by leptin. In accordance with GSK-3β being involved in tau phosphorylation, the protective effects of leptin involve PI 3-kinase (PI3K) activation and inhibition of GSK-3β. Aβ -driven synaptic targeting of tau was associated with the removal of GluA1-containing AMPARs from synapses, which was also inhibited by leptin-driven inhibition of GSK-3β. Direct application of oligomeric tau to hippocampal neurons caused internalisation of GluA1-containing AMPARs and this effect was blocked by prior application of leptin. Similarly, leptin prevented the ability of tau to block induction of activity-dependent long-term potentiation (LTP) at hippocampal SC-CA1 synapses. These findings increase our understanding of the neuroprotective actions of leptin in the early pre-clinical stages of AD and further validate the leptin system as a therapeutic target in AD.
淀粉样蛋白-β(Aβ)和过度磷酸化的 tau 是阿尔茨海默病(AD)的关键标志,这两种蛋白质的积累与海马突触功能障碍有关。最近的证据表明,Aβ 导致 tau 从轴突错误定位到突触,导致 AMPA 受体(AMPAR)内化和兴奋性突触功能受损。这些 tau 驱动的突触损伤被认为是 AD 认知缺陷的基础。因此,限制 tau 的突触毒性作用可能预防 AD 相关的认知缺陷。越来越多的证据将瘦素功能障碍与更高的 AD 风险联系起来,许多研究已经确定了瘦素在 AD 模型中对 Aβ诱导的毒性具有神经保护作用。然而,尚不清楚瘦素是否能预防与 tau 相关的突触功能障碍。在这里,我们发现 Aβ 显著增加了海马神经元中树突和突触tau 和 p-tau 的水平,而瘦素则阻断了这些效应。由于 GSK-3β 参与 tau 磷酸化,瘦素的保护作用涉及 PI 3-激酶(PI3K)的激活和 GSK-3β 的抑制。Aβ 驱动的 tau 突触靶向与 GluA1 包含的 AMPAR 从突触中的去除有关,这也被瘦素驱动的 GSK-3β 抑制所抑制。寡聚 tau 直接应用于海马神经元会导致 GluA1 包含的 AMPAR 内化,而瘦素的预先应用则阻断了这一效应。同样,瘦素阻止了 tau 阻断海马 SC-CA1 突触上的活性依赖性长时程增强(LTP)诱导的能力。这些发现增加了我们对瘦素在 AD 早期临床前阶段的神经保护作用的理解,并进一步验证了瘦素系统作为 AD 的治疗靶点的合理性。